KTTAW | Pasithea Therapeutics Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0201 - 0.0201
52 Week Range	0.0201 - 0.0201
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	354
Average Volume	N/A
Shares Outstanding	198,427,313
Market Cap	3,991,571
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-09-15

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	KTTAW

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.

KTTAW's peers: BBLGW, DRMAW, KTTA, BFRIW, LIXTW, JSPRW, MTEKW, IVDAW, NRSNW, RVSNW, NXGLW

*Chart delayed

Analyzing fundamentals for KTTAW we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see KTTAW Fundamentals page.

Watching at KTTAW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on KTTAW Technicals page.